64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer

Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227.

Authors

S Sasada¹, H Kurihara², T Kinoshita³, M Yoshida⁴, N Honda², T Shimoi¹, A Shimomura¹, M Yunokawa¹, K Yonemori¹, C Shimizu¹, A Hamada⁵, Y Kanayama⁶, Y Watanabe⁶, Y Fujiwara¹, K Tamura¹

Affiliations

¹ Department of Breast and Medical Oncology.
² Department of Diagnostic Radiology.
³ Department of Breast Surgery.
⁴ Department of Pathology and Clinical Laboratories, National Cancer Center Hospital.
⁵ Division of Molecular Pharmacology and Pharmacokinetics, National Cancer Center Research Institute, Tokyo.
⁶ RIKEN Center for Life Science Technologies, Hyogo, Japan.

PMID: 28505219
DOI: 10.1093/annonc/mdx227

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized*
Breast Neoplasms / diagnostic imaging*
Breast Neoplasms / enzymology*
Female
Humans
Immunohistochemistry
Organometallic Compounds*
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals*
Receptor, ErbB-2 / biosynthesis*
Trastuzumab

Substances

64Cu-DOTA-trastuzumab
Antibodies, Monoclonal, Humanized
Organometallic Compounds
Radiopharmaceuticals
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab